|Bid||66.70 x 900|
|Ask||69.90 x 2900|
|Day's Range||65.42 - 66.81|
|52 Week Range||36.92 - 72.81|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||51.26|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.67|
BAUDETTE, Minn. , Feb. 27, 2019 /PRNewswire/ -- For the full year ended December 31, 2018 : Record net revenues of $201.6 million , an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Many investors are still learning about the various metrics thatRead More...
BAUDETTE, Minn. , Feb. 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2018 financial results on ...
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In 2013 Arthur Przybyl was appointed CEO of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced that it has entered an amended and restated five-year Senior Secured Credit Facility (the "Facility") for up to $265.2 million with its existing syndicate of bank lenders (the "Bank Group"). The Facility amends ANI's current $125 million Senior Secured Credit Facility and is structured to provide ANI flexibility in refinancing its 3.00% Convertible Senior Notes due 2019 ("the Convertible Notes"). The principal feature of the Facility is a new $118.0 million Delayed Draw Term Loan available to refinance ANI's Convertible Notes maturing in December 2019.
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]
BAUDETTE, Minn., Dec. 7, 2018 /PRNewswire/ -- (ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "Notes"). ANI has agreed to repurchase $25.0 million aggregate principal amount of Notes for a total of $26.1 million in cash, including accrued but unpaid interest up to but excluding the closing date for the transactions. In connection with the contemplated repurchase of Notes, ANI has also entered into an agreement with the dealer party to certain convertible note hedge transactions related to the Notes to unwind a corresponding portion of such convertible note hedge transactions.
While small-cap stocks, such as ANI Pharmaceuticals Inc (NASDAQ:ANIP) with its market cap of US$655m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
Let???s see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.
BAUDETTE, Minn., Nov. 15, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period. ANI's President and CEO, Arthur S. Przybyl, said, "I want to thank our employees for their hard work and contributions, which have enabled ANI to be listed on Deloitte's Technology Fast 500™ for the second year in a row.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ANI (ANIP) delivered earnings and revenue surprises of 5.74% and 0.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Baudette, Minnesota-based company said it had profit of 42 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.29 per share. The drugmaker posted revenue of $50.7 million in ...
BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million ...
BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, ...
BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market. ANI acquired the NDA for Brethine® (terbutaline sulfate) tablets in December 2016. Arthur S. Przybyl, ANI's President and CEO stated, "ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs.
BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®. The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. Atacand HCT® is indicated for the treatment of hypertension.